AAN 2025: Less off time, more good on time with long-term Onapgo
Treatment for up to three years with Onapgo (apomorphine hydrochloride) — approved in the U.S. earlier this year as…
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Treatment for up to three years with Onapgo (apomorphine hydrochloride) — approved in the U.S. earlier this year as…
Although physical exercise has well-established benefits for people with Parkinson’s disease, too much of it may worsen fatigue and…
Vyalev (foscarbidopa and foslevodopa) demonstrated a favorable long-term safety and tolerability profile, along with sustained motor symptom control,…
Nitrase Therapeutics’ NDC-0524, an antibody therapy for Parkinson’s disease, significantly reduced alpha-synuclein aggregation and spreading in mouse models of the…
A new collaborative effort between Mayo Clinical Laboratories and Amprion will expand access to the diagnostic company’s…
Researchers at the University of Delaware have developed a model that combines artificial intelligence with magnetic resonance elastography (MRE) to…
Newronika is preparing for the commercial launch of AlphaDBS — a next-generation adaptive deep brain stimulation (DBS) system…
Neuropacs‘ MRI-based artificial intelligence (AI) technology demonstrated 96% accuracy in distinguishing Parkinson’s disease from atypical parkinsonism — including…
Parkinson Italia — a network of 30 associations for patients and caregivers in Italy — is backing an initiative…
Most people with early-stage Parkinson’s disease have sleep disturbances, with many having more than one at the same time,…
Get regular updates to your inbox.